NeOnc Technologies Secures $14.1M in Private Placements at $7.20/Share for NEO216
Summary
NeOnc Technologies has successfully raised approximately $14.1 million through four private placements conducted between January and April 2026. This financing is earmarked to fund the preclinical trials for its key drug candidate, NEO216. Notably, the common stock was sold at $7.20 per share, a significant premium to the current market price of $4.78, which signals strong investor confidence and mitigates the dilutive effect for existing shareholders. This comprehensive update follows an earlier 8-K filing on April 16th that disclosed a $13 million private placement specifically for Q1 2026, with this news providing the full scope of the capital raise through April. The secured capital is critical for advancing NTHI's pipeline, and investors will now monitor the progress of the NEO216 program.
At the time of this announcement, NTHI was trading at $4.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $119.1M. The 52-week trading range was $3.20 to $12.99. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.